No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
PHR240621C22500
- 0.10
- -1.15-92.00%
15min DelayClose May 31 15:59 ET
0.20High0.10Low
0.20Open1.25Pre Close10 Volume72 Open Interest22.50Strike Price160.00Turnover54.24%IV19.45%PremiumJun 21, 2024Expiry Date0.00Intrinsic Value100Multiplier19DDays to Expiry0.10Time Value100Contract SizeAmericanOptions Type0.0953Delta0.0720Gamma189.20Leverage Ratio-0.0105Theta0.0009Rho18.03Eff Leverage0.0073Vega
Intraday
- 5D
- 1D
News
Phreesia Falls After Earnings, But Analysts See Upside -- Market Talk
1625 ET - Phreesia falls 11% after quarterly results, although the patient-intake software company said it had a "solid start" to the year and some analysts had favorable comments. D.A. Davidson says
Phreesia | 10-Q: Quarterly report
Why SentinelOne Shares Are Trading Lower By 16%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Shares of SentinelOne, Inc. (NYSE:S) shares fell sharply during Friday's session after the company posted mixed first-quarter results.SentinelOne reported quarterly losses of 23 cents per share, which
Phreesia Is Maintained at Buy by Canaccord Genuity
Phreesia Is Maintained at Buy by Canaccord Genuity
Express News | Canaccord Genuity Maintains Buy on Phreesia, Lowers Price Target to $34
Phreesia Price Target Maintained With a $30.00/Share by JMP Securities
Phreesia Price Target Maintained With a $30.00/Share by JMP Securities
Comments
Investor confidence, reflected in a high P/S ratio and increasing share prices despite fluctuations, suggests anticipated persistent growth in Phreesia. Caution advised over sole reliance on price-to-sales ratios for investment decisions.
Phreesia, Inc.'s (NYSE:PHR) P/S Is Still On The Mark Following 43% Share Price Bounce
Gainers:
• $Okta(OKTA.US$ +15.8% (In reaction to earnings)
• $StoneCo(STNE.US$ +12.9% (In reaction to earnings)
• $Turning Point Therapeutics(TPTX.US$ +116.8% (Bristol Myers Squibb (BMY) will acquire Turning Point Therapeutics for $76,00 per share; expected to be accretive to Non-GAAP earnings per share beginningin2025)
• $Amylyx Pharmaceuticals(AMLX.US$ +24.9% (receives PDUFA date extension for AMX0035; scheduled for September ...
• $Okta(OKTA.US$ +15.8% (In reaction to earnings)
• $StoneCo(STNE.US$ +12.9% (In reaction to earnings)
• $Turning Point Therapeutics(TPTX.US$ +116.8% (Bristol Myers Squibb (BMY) will acquire Turning Point Therapeutics for $76,00 per share; expected to be accretive to Non-GAAP earnings per share beginningin2025)
• $Amylyx Pharmaceuticals(AMLX.US$ +24.9% (receives PDUFA date extension for AMX0035; scheduled for September ...
25
2
Upgrades
• $CDW Corp(CDW.US$: Stifel Upgrades to Buy from Hold - PT $210 (from $200)
• $Corteva(CTVA.US$ : Loop Capital Upgrades to Buy from Hold - PT $69
• $CoreCivic, Inc.(CXW.US$ : Wedbush Upgrades to Outperform from Neutral - PT $17 (from $10.85)
• $Delta Air Lines(DAL.US$ : Barclays Upgrades to Overweight from Equalweight - PT $60 (from $42)
• $H.B. Fuller(FUL.US$ : Baird Upgrades to Outperform from Neutral - PT $85
• $Huntington Ingalls Industries(HII.US$ : Cowen U...
• $CDW Corp(CDW.US$: Stifel Upgrades to Buy from Hold - PT $210 (from $200)
• $Corteva(CTVA.US$ : Loop Capital Upgrades to Buy from Hold - PT $69
• $CoreCivic, Inc.(CXW.US$ : Wedbush Upgrades to Outperform from Neutral - PT $17 (from $10.85)
• $Delta Air Lines(DAL.US$ : Barclays Upgrades to Overweight from Equalweight - PT $60 (from $42)
• $H.B. Fuller(FUL.US$ : Baird Upgrades to Outperform from Neutral - PT $85
• $Huntington Ingalls Industries(HII.US$ : Cowen U...
19
Gainers:
• $Clovis Oncology(CLVS.US$ +40.6% (Rubraca significantly improves progression-free survival in first-line maintenance treatment in women with ovarian cancer regardless of their biomarker status in phase 3 athena-mono trial)
• $Dare Bioscience(DARE.US$ +13.61% (Organon and Dar Bioscience have entered into an agreement whereby Organon will license global rights to XACIATO)
• $KULR Technology(KULR.US$ +9.5% (secured a battery sa...
• $Clovis Oncology(CLVS.US$ +40.6% (Rubraca significantly improves progression-free survival in first-line maintenance treatment in women with ovarian cancer regardless of their biomarker status in phase 3 athena-mono trial)
• $Dare Bioscience(DARE.US$ +13.61% (Organon and Dar Bioscience have entered into an agreement whereby Organon will license global rights to XACIATO)
• $KULR Technology(KULR.US$ +9.5% (secured a battery sa...
14
Read more